SGLT2 inhibitors are prioritized for patients with chronic kidney disease (CKD), heart failure, or high risk of heart failure, due to their proven benefits in reducing cardiovascular morbidity and mortality17. This evidence concerns the gene SLC5A2 and heart failure.